人类纤溶酶原激活物抑制物-1基因多态性与2型糖尿病血管内皮功能的关系  

Relationship between plasminogen activator inhibitor 1 gene polymorphism and the level of endothelium-dependent vasodilatation in patients with type 2 diabetes

作　　者：颜晓芳[1] 潘时中[1] 严孙杰[1] 张松菁[1] 

机构地区：[1]福建医科大学附属第一医院内分泌科,福州350005

出　　处：《中国综合临床》2008年第7期708-710,共3页Clinical Medicine of China

摘　　要：目的探讨人类纤溶酶原激活物抑制物-1（PAI-1）基因4G／5G多态性与2型糖尿病（T2DM）患者内皮依赖性血管舒张功能（EDF）的关系。方法采用特异性多聚酶链反应技术检测66例T2DM患者和33例健康对照组PAI-1基因4G／5G多态性；利用B型超声检测T2DM患者EDF；同时检测PAI-1和纤维蛋白原。结果T2DM患者与健康对照组基因型分布频率均符合Hardy-Weinberg平衡，差异无统计学意义（P〉0．05）。T2DM患者比健康对照组具有更高的PAI-1、纤维蛋白原水平。T2DM患者PAI-1基因4G／4G型PAI-1水平明显高于其他两型。EDF明显低于其他两型（P〈0．05）。结论PAI-1基因多态性可能影响T2DM患者的EDF。Objective To investigate the relationship between the polymorphisms of plasminogen activator inhibitor-1 （ PAI-1 ） gene and the level of endothelium-dependent vasodilatation （EDF） in patients with type 2 diabetes（T2DM）. Methods The polymorphisms of PAI-1（4G/SG） gene were determined by polymerase chain reaction （PCR） and the EDF was assessed by non-invasive high resolution B-mode ultrasonography in 66 T2DM patients and 33 controls. Plasma plasminogen activator inhibitor type-1 （ PAI-1 ） and fibrinogen （ Fg ） were measured. Results Frequencies of PAI- 1 alleles and genotypes in T2DM patients and controls were all in accordance with the Hardy Weinberge quilibrium,without significant differences between T2DM patients and controls（P 〉 0.05）. PAI-1 and Fg were significantly higher in T2DM patients than in controls. There were significant differences in EDF and PAI- lamong different genotypes of PAI-1 （ P 〈 0.05 ）. Conclusion The PAI-1 genotype may affect EDF in T2DM patients,

关 键 词：2型糖尿病 血浆纤溶酶原激活物抑制剂 基因 多态性 

分 类 号：R541.4[医药卫生—心血管疾病]